ABL Part of Team Awarded $900 M IDIQ Contract by US Army for Medical Product Research and Development

ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.  

The award is an indefinite delivery/indefinite quantity (IDIQ) contract with a 5-year base period of performance plus five one-year options, and a total contract value of $900 million for all awardees, if all options are exercised.  

As a member of the Engility team, ABL will have the opportunity to apply its comprehensive project management, product development, GMP manufacturing, and testing services in support of medical product research to support the Nation’s military.  

Thomas VanCott, Ph.D., ABL’s President and CEO said, “The required breadth of product development expertise for the scope of this contract lies within ABL’s core competency. With over 50 years of experience conducting biomedical research, as well as manufacturing vaccines and therapeutics for the U.S. Government, ABL provides a unique combination of scientific expertise coupled with operational excellence to address the complex medical issues facing our military today.”  Dr. VanCott continued, “ABL has a proven track record of rapidly assessing highly technical projects and bringing together the right mix of in-house capabilities and external resources to complete mission objectives, and we look forward to contributing to the advancement of critical medical research and products required by the Army and other Department of Defense entities.”